Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02987010 | Phase 2 Study of IDH305 in Low Grade Gliomas | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Oct 11, 2017 | clinicaltrials |
| NCT01251172 | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 20, 2017 | clinicaltrials |
| NCT00109798 | Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma | withdrawn | N/A | 0 | The Methodist Hospital Research InstituteOTHER | 0 | Sep 19, 2017 | clinicaltrials |
| NCT00837174 | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study(COMBOSTAT) | withdrawn | Phase 2 | 0 | The Methodist Hospital Research InstituteOTHER | 0 | Sep 19, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01489410 | Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | withdrawn | N/A | 0 | University of MinnesotaOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT03138395 | iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML(iCare3) | withdrawn | — | 0 | University of FloridaOTHER | 0 | Aug 31, 2017 | clinicaltrials |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT02950792 | MRI Adaptive Replanning Using ViewRay | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT01833767 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | withdrawn | Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma(MUKfourteen) | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01398124 | Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer | withdrawn | N/A | 0 | Milton S. Hershey Medical CenterOTHER | 0 | Aug 22, 2017 | clinicaltrials |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start | withdrawn | — | 0 | BayerINDUSTRY | 1 | Aug 16, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT02959359 | DAA in the Risk of Recurrence After Curative Treatment of HCC | withdrawn | Phase 4 | 0 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 0 | Aug 7, 2017 | clinicaltrials |
| NCT02663258 | A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)(ADAPTeM) | withdrawn | Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT00257335 | Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer | withdrawn | Phase 2 | 0 | Nilam RamsinghaniOTHER | 0 | Jul 31, 2017 | clinicaltrials |
| NCT02639234 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Gradalis, Inc.INDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT02489266 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 27, 2017 | clinicaltrials |
| NCT01260103 | Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma | withdrawn | Phase 3 | 0 | Burzynski Research InstituteOTHER | 0 | Jul 26, 2017 | clinicaltrials |
| NCT03141398 | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group(CGMs) | withdrawn | — | 0 | Hamad Medical CorporationINDUSTRY | 0 | Jul 26, 2017 | clinicaltrials |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 21, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00899145 | Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT03042013 | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT02321982 | Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery | withdrawn | N/A | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | Jul 6, 2017 | clinicaltrials |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01095523 | Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01130623 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01182883 | A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01236586 | RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors(I-CREST) | withdrawn | N/A | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | withdrawn | Phase 1 / Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01148082 | School Response to Families Who Have Children With Cancer | withdrawn | — | 0 | Stanford UniversityOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02495636 | Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00637117 | Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma. | withdrawn | Phase 1 / Phase 2 | 0 | Baylor Research InstituteOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02194374 | Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | withdrawn | Early Phase 1 | 0 | University of PittsburghOTHER | 0 | Jun 8, 2017 | clinicaltrials |
| NCT02570958 | ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors(ENB-RIGGS) | withdrawn | Phase 1 | 0 | St. Joseph's Healthcare HamiltonOTHER | 0 | Jun 5, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 11, 2017source: clinicaltrials